135 related articles for article (PubMed ID: 24251412)
1. Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A.
Steele MR; Nagel K; Chan AK
Haemophilia; 2014 Jan; 20(1):e100-1. PubMed ID: 24251412
[No Abstract] [Full Text] [Related]
2. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A.
Young JH; Liu HC; Hsueh EJ; Huang ML; Peng CT; Chen RL; Maas-Enriquez M; Achilles K
Haemophilia; 2009 Jul; 15(4):968-70. PubMed ID: 19473407
[No Abstract] [Full Text] [Related]
3. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
[TBL] [Abstract][Full Text] [Related]
4. Cumulative analysis of inhibitor formation in patients with haemophilia A treated with sucrose-formulated recombinant factor VIII.
Bajwa N; Enriquez MM; Gorina E; Lemm G
Haemophilia; 2009 Mar; 15(2):597-600. PubMed ID: 19187195
[No Abstract] [Full Text] [Related]
5. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
[TBL] [Abstract][Full Text] [Related]
7. Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A.
Kremer Hovinga ICL; Schutgens REG; van der Valk PR; van Vulpen LFD; Mauser-Bunschoten EP; Fischer K
Haemophilia; 2018 Jul; 24(4):e280-e283. PubMed ID: 30044044
[No Abstract] [Full Text] [Related]
8. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis in children with haemophilia - the Polish experience.
Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
[No Abstract] [Full Text] [Related]
10. Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A.
Smith MP; Rupon J; Wali Y; Rimawi H; Korth-Bradley J; Smith L; Rendo P
Haemophilia; 2020 Sep; 26(5):e232-e235. PubMed ID: 32497363
[No Abstract] [Full Text] [Related]
11. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
Taki M; Shirahata A
Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
[TBL] [Abstract][Full Text] [Related]
12. Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa.
Abrantes JA; Nielsen EI; Korth-Bradley J; Harnisch L; Jönsson S
Clin Pharmacol Ther; 2017 Dec; 102(6):977-988. PubMed ID: 28437834
[TBL] [Abstract][Full Text] [Related]
13. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
[TBL] [Abstract][Full Text] [Related]
14. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
15. Current status of clinical studies of recombinant factor VIII (recombinate) in patients with hemophilia A. Recombinate Study Group.
Bray GL
Transfus Med Rev; 1992 Oct; 6(4):252-5. PubMed ID: 1421824
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics of factor VIII in hemophilia A patients assessed by frequency response method.
Durisová M; Dedík L; Bátorová A; Sakalová A; Hedera J
Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):217-26. PubMed ID: 9646284
[TBL] [Abstract][Full Text] [Related]
17. Home management of hemophilia A.
Van Eys J
J Tenn Med Assoc; 1971 May; 64(5):407-10. PubMed ID: 5091669
[No Abstract] [Full Text] [Related]
18. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study.
Rivard GE; Rothschild C; Toll T; Achilles K
Haemophilia; 2013 May; 19(3):449-55. PubMed ID: 23510123
[TBL] [Abstract][Full Text] [Related]
19. Management of a premature infant with moderate haemophilia A using recombinant factor VIII.
Gale RF; Hird MF; Colvin BT
Haemophilia; 1998 Nov; 4(6):850-3. PubMed ID: 10028309
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII.
Kempton CL; Meeks SL; Donald Harvey R; Abshire TC
Haemophilia; 2011 Jan; 17(1):155-6. PubMed ID: 20579112
[No Abstract] [Full Text] [Related]
[Next] [New Search]
